Mass marriage

India, April 28 -- Suttur Srikshetra, apart from organising mass marriages during the Jathra Mahotsava, is also organising mass marriages every month since February 2009. All sections of society are e... Read More

Ajay Pal Sharma: All about the dentist-turned-IPS-officer in spotlight during West Bengal polls

New Delhi, April 28 -- Ajay Pal Sharma, the Uttar Pradesh batch IPS officer, who is also known as an 'encounter specialist', has become the focal point of political tensions between the TMC and the BJ... Read More

Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More

Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More

Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More

Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, April 28 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More

• ««
• «
• 3587
• 3588
• 3589
• 3590
• 3591
• 3592
• 3593
• 3594
• 3595
• 3596
• »
• »»